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with subcutaneous glatiramer acetate
injection—a case report
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Abstract
Background: Glatiramer acetate is worldwide used as first line treatment in relapsing remitting multiple sclerosis.
Local skin reactions associated with glatiramer acetate are common, however, only isolated cases of severe local
injection site reactions known as Nicolau Syndrome have been reported so far.
Case presentation: We describe the case of a recurrent Nicolau Syndrome occurred during longstanding
glatiramer acetate treatment in a woman with multiple sclerosis. The haemorrhagic patch necrotized and was
treated locally as a deep second degree burn with excision of dead skin tissue and was healed. Treatment with
glatiramer acetate was definitely suspended.
Conclusions: GA injections can be complicated by isolated or recurrent Nicolau Syndrome, a potentially life-
threatening condition of which neurologists should be aware.
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Background
Glatiramer acetate (GA) [1] is worldwide one of the
most frequently prescribed immune modulatory treat-
ment for multiple sclerosis (MS) and considered both an
efficacious and safe compound [2, 3]. GA may cause
common albeit generally unserious local skin reactions.
These may have potentially negative impact on patient’s
health-related quality of life [4] and reduce compliance
and adherence, therefore representing a major limitation
of GA use [5]. The most common GA related skin reac-
tions include local redness, erythema, swelling, pain,
pruritus, bruising, irritation, inflammation, induration of
the skin around an injection site, or lipoatrophy, devel-
oping in 7–90 % of treated patients [3, 4].
Only single cases of a severe local injection site reac-
tion known as Nicolau Syndrome (NS) have been re-
ported during GA treatment so far [6–12]. The typical
NS presentation is pain around the injection site soon
after injection followed by erythema developing within
hours with a livid discoloration at the injection site.
Irregular lightning-like extensions therefore develop per-
ipherally. The epidermis is intact during the first days
and an indurated infiltrate is palpable at the injection
site. After several days a central necrosis of the size cor-
responding to the indurated infiltrate develops. After
several weeks, a well-demarcated necrotic area remains.
We report the case of a recurrent Nicolau Syndrome
(NS) occurring during GA treatment.
Case presentation
The patient is a 58 year-old female with relapsing remit-
ting MS treated with subcutaneous GA since 2006, and
otherwise unremarkable medical history. She presented
at our department with a painful livedoid and haemor-
rhagic skin lesion that developed on her left abdomen
approximately 24 h after GA injection. She reported cor-
rect injection practice.
She had no fever. Blood cell count, C-reactive protein,
renal function, creatine kinase (CK), IgE, autoimmune
screening, lupus anticoagulants and cryoglobulins were
unremarkable. Superficial ultrasonography at skin lesion
showed diffuse oedema without fluid collections. The
patient was dismissed with symptomatic non-steroidal
anti-inflammatory treatment and GA was stopped.
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After 2 days, a livedoid violaceous skin patch with
dendritic extensions below the injection site became ap-
parent (Fig. 1a and b). At surgical evaluation at the
Emergency Department cellulitis was suspected and a
surgical revision proposed to avoid potentially lethal
complications (such as sepsis and renal failure following
rhabdomyolysis). Considering the negative inflammatory
parameters and normal renal and CK values, we referred
her before surgery to the Dermatology department for
further counselling. Here, a NS was suspected and con-
firmed by a skin biopsy showing coagulative necrosis of
dermal collagen and local adipose tissue, as well as sev-
eral hyaline thrombi inside small and medium-sized
blood vessels (Fig. 2), without skin infection (cellulitis).
Bacteriological culture of lesion samples grew only resi-
dent flora. The livedoid figures around the central haem-
orrhagic skin lesions disappeared spontaneously after a
week. The haemorrhagic patch of NS necrotized (Fig. 1c).
The skin necrosis was limited at the dermis and was re-
moved by a surgical debridement. It was treated with a
continuing multifunctional dressing to cleanse, fill, ab-
sorb and moisten the wound. A healing by second
intention was obtained in 2 months after first evaluation.
GA was definitively suspended. At that time, the patient
reported that in 2007 a similar lesion had occurred after
GA injection in her right abdomen. She experienced im-
mediate and unusual local pain with subsequent appear-
ance of a dark red area around the injection site. A
central dark lesion developed within 2 days leading her
to the emergency department. The lesion was initially
treated conservatively, however, a surgical excision was
required after a few days. No histological examination
was performed at that time. The lesion evolved into a
slightly depressed white scar. A recurrent NS was there-
fore diagnosed.
Conclusions
We describe the case of recurrent NS under GA treat-
ment in a patient with MS.
NS (or Embolia cutis medicamentosa) is a very rare
and potentially life threatening complication following
injection of several drugs [13]. It consists of a local vas-
culitis which can evolve in subcutaneous, fat or muscle
tissue necrosis. NS is mostly described as a complication
of a variety of intra-muscular drug preparations, how-
ever it has also been reported to occur with sc. injec-
tions, particularly GA and interferons [14]. Typically, NS
onset is represented by pain around the injection site,
which is followed by erythema progressively evolving in
a livedoid and then haemorrhagic patch. Finally, aseptic
necrosis of skin, subcutaneous fat, and muscle tissue can
occur [13].
The cause of NS seems to be related to the injection
itself rather than to the injected compound or even the
administration route (i.e. intramuscular or subcutane-
ous). Its pathogenesis is not fully understood, and only
hypothesis have been proposed so far. An unintended
intra-periarterial or perinervous injection might induce
severe pain and consequently sympathetic nerve medi-
ated vasospasm. This, in turn, may lead to local necrosis.
Fig. 1 a Nicolau Syndrome (NS) on left abdomen at first dermatological evaluation 2 days after onset. b Magnification of the NS lesion
highlighting an erythematous, purpuric and haemorrhagic patch, at the site of the subcutaneous glatiramer acetate (GA) injection. Surrounding
livedoid reticular patch as sign of vascular damage. c Three weeks after GA injection the livedoid patch disappeared. A skin necrosis induced by
the cutaneous ischemia an atonic superficial wound developed thereafter
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Injection itself might also cause embolic occlusion of
small skin arteries, as well as marked arterial wall in-
flammation ultimately causing tissue necrosis.
NS is per se rare and only few cases have been previ-
ously reported after GA injection so far [7–12]. Notably,
only one of these was recurrent [9]. Predominantly fe-
males were involved as in our case probably reflecting
MS epidemiology. Lesion site was heterogeneous among
cases (abdomen, tight, arm, buttock), and NS occurred
generally years after GA treatment initiation. No specific
trigger factors were identified, and the injection tech-
nique was mostly correct with the exception of a single
patient referring difficulties with the injection preceding
NS onset [8]. In two cases no specific treatment was per-
formed, one resolved completely [10] and the second
one evolved in a slightly depressed scar [11]. The
remaining patients where treated with surgical excision
of the necrotic area, vasodilatative drugs, heparine, fusi-
dic acid and steroids [7, 8, 11, 12] with variable results
ranging from no sequelae [8] to muscle involvement [6].
Various treatments have been used for NS, however,
none of them has become standard of care. In the ma-
jority of cases treatment of NS remains conservative,
with analgesics, antibiotics, and dressing. If tissue necro-
sis is present, surgical removal is performed first, and
advanced dressings according to the extent, depth and
severity of the wound is therefore used. In wide lesions
skin grafts or flaps may be required [15].
It has been suggested that the occurrence of a NS does
not contraindicate continuation of GA treatment, as NS
is believed to be mainly a consequence of the injection
technique rather than of the drug itself [9]. We were not
able, however, to identify incorrect injection practice in
our patient who nevertheless experienced a recurrence
of NS, possibly suggesting individual predisposition and/
or a role of the specific compound.
Neurologists should be aware of NS as possible conse-
quence of GA injection, as its course might include le-
thal complications such as sepsis and renal failure
following rhabdomyolysis.
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Fig. 2 Histological picture of the patient’s skin biopsy. a partly necrotic and elevated epidermis (dashed arrows) due to thrombosized small
vessels (solid arrows) in the upper dermis with only sparse cellular inflammation. b haematoma in the deeper part of dermis (solid arrow).
c cellular inflammation in the deeper dermis (solid arrow) and panniculitis (dashed arrow) with coagulative necrosis of dermal collagen and local
adipose tissue. Stain: haematoxylin-eosin, a: x 200, b: x 100, c: x 40. Software: ProgRes CapturePro v2.8.8
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